



1 **Supplementary Materials:**




2

3 **Supplementary Figure 1. The research workflow.**



Supplementary Figure 2. Assessment of Harmony batch integration and hierarchical clustering transitions across multiple resolutions. (A) Evaluation of over-correction by Harmony integration based on silhouette width. Left: Batch dimension; Right: CellType dimension. **(B)** Hierarchical tree plot of single-cell clustering across increasing resolutions (epithelial cells). **(C)** Hierarchical tree plot of single-cell clustering across increasing resolutions (T cells). **(D)** Hierarchical tree plot of single-cell clustering across increasing resolutions (Myeloid cells).




13

14 **Supplementary Figure 3. Global single-cell transcriptomic landscape and cell type**

cells derived from NSCLC primary tumors (Lung Cancer), mLN. Each subcluster is annotated by its top marker genes. **(F)** The heatmap shows the consistency of the tumor epithelial subpopulations in the new dataset and the original dataset. **(G)** The stacked bar chart shows the proportions of each tumor subgroup in the Lung Cancer and mLN.


37



38

Supplementary Figure 5. Differential expression and pathway analysis between metastatic lesions and primary lung cancer. **(A)** Volcano plot of differentially expressed genes (DEGs) between metastatic lesions and primary lung cancer. Blue dots represent significantly downregulated genes, red dots represent significantly upregulated genes, and gray dots represent non-significant changes. The horizontal dashed line indicates the significance threshold ($p < 0.05$). **(B)** Bar plot of pathway enrichment analysis using Gene Set Variation Analysis (GSVA) comparing metastatic lesions and primary lung cancer. The x-axis represents the t-value of GSVA scores; red bars indicate upregulated pathways, blue bars downregulated pathways, and gray bars pathways with no significant difference. **(C)** Gene Ontology (GO) and KEGG pathway enrichment analysis of DEGs in mBrain compared to primary tumors. **(D)** GO and KEGG pathway enrichment analysis of DEGs in mLN compared to primary tumors. **(E)** Comparison of UPR pathway enrichment scores and XBP1, ATF6, and ATF4 expression between Lung and mLN samples.

51



Supplementary Figure 7. Myeloid cell subtyping, sample distribution, and tissue enrichment analysis in NSCLC brain and lymph node metastases. (A) UMAP visualization of myeloid cells in NSCLC mBrain and mLN, grouped by tissue origin. The plot shows the overall distribution of myeloid cells across different tissue microenvironments. **(B)** Stacked bar plot showing the proportional distribution of myeloid cell subsets in each sample. **(C)** Heatmap of myeloid cell subset enrichment across different tissues. Yellow indicates significant enrichment of the subset in the corresponding tissue, while blue indicates lower enrichment. **(D)** Dot plot showing the expression levels of key immunosuppressive in myeloid cells of metastatic sites (mLN) compared to normal tissues.

65

66

67

68

69

70


71

72


73

74

75



Supplementary Figure 8. Prognostic value of metastasis-associated tumor subclusters in TCGA LUAD cohort and box plots of ssGSEA signature scores. (A) Univariate Cox regression analysis of prognostic factors. Forest plot showing the hazard ratios (HRs) and p values for each tumor (C1 – C14) and epithelial(C1,C2) subcluster in relation to overall survival of LUAD patients from The Cancer Genome Atlas (TCGA). **(B)** The relationship between high/low C14_PBK_Tumor expression and overall survival. **(C)** Box plot for each tumor and epithelial subcluster ssGSEA signatures score. **(D)** Box plot for CD4⁺/CD8⁺/γδT cells related ssGSEA signatures score. **(E)** Box plot for macrophages, monocytes, DC and neutrophils related ssGSEA signatures score.



Supplementary Figure 9. mIHC images showing the expression and spatial distribution of CD68⁺/CD163⁺, PD 1⁺/ CD8⁺, XBP1⁺/ATF6⁺/ATF4⁺ makers in Mets0 and Mets1 NSCLC tissues. (A-D) The sample number is indicated at the top of the picture, and the sample information can be found in Supplementary Table 5. Scale bars: 50 μ m.